Gökhan Batur

Gökhan Batur has more than 18 years of healthcare industry experience. Until recently, he has been the CEO at Polyphor, a publicly traded Swiss Biotechnology company focused to oncology and infectious disease. At Polyphor, he has led a large international Phase 3 trial for the company’s immuno-oncology program with balixafortide in metastatic breast cancer and brought a novel class program in cystic fibrosis from GLP to Phase 1 focusing on treating chronic infections. Before joining Polyphor, he assumed various management roles at Merck Co Inc. known as MSD outside of the US, lastly serving as Executive Director, Global Head, Antibiotics, responsible for leading the entire Merck antibiotics portfolio managing multiple in-line, launch and pipeline products and sales of ~2 billion dollars.